These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 9695725

  • 1. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
    Trocóniz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO.
    Clin Pharmacol Ther; 1998 Jul; 64(1):106-16. PubMed ID: 9695725
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 3. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC, Debilly B, Rascol O, Lees AJ, Durif F.
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [Abstract] [Full Text] [Related]

  • 4. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.
    Clin Neuropharmacol; 2008 Sep; 31(1):2-18. PubMed ID: 18303486
    [Abstract] [Full Text] [Related]

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 6. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J, US01 Study Team.
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [Abstract] [Full Text] [Related]

  • 7. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 8. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, TC-INIT Study Group.
    Eur Neurol; 2005 Jan 15; 53(4):197-202. PubMed ID: 15970632
    [Abstract] [Full Text] [Related]

  • 9. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.
    Ann Neurol; 2011 Jan 15; 69(1):111-8. PubMed ID: 21280081
    [Abstract] [Full Text] [Related]

  • 10. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, Matsumoto M.
    Hiroshima J Med Sci; 2011 Sep 15; 60(3):57-62. PubMed ID: 22053701
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 15; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 12. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.
    Clin Neuropharmacol; 2001 May 15; 24(3):150-7. PubMed ID: 11391126
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H, Harder S, Bürklin F, Demisch L, Fischer PA.
    Clin Neuropharmacol; 1998 May 15; 21(2):86-92. PubMed ID: 9579293
    [Abstract] [Full Text] [Related]

  • 14. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
    Kulisevsky J.
    Neurologia; 1999 May 15; 14(7):349-58. PubMed ID: 10570622
    [Abstract] [Full Text] [Related]

  • 15. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr 15; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 16. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J.
    Clin Ther; 2001 Jun 15; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct 15; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 18. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A.
    J Neurol Neurosurg Psychiatry; 2000 May 15; 68(5):589-94. PubMed ID: 10766888
    [Abstract] [Full Text] [Related]

  • 19. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
    Ruottinen HM, Rinne UK.
    Clin Neuropharmacol; 1996 Aug 15; 19(4):283-96. PubMed ID: 8828991
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K, ComQol Study Group.
    Acta Neurol Scand; 2005 Jan 15; 111(1):21-8. PubMed ID: 15595934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.